renal-cell carcinoma (advanced) clinical trials results

apitolisib versus everolimus
Powles, 2014	versus
axitinib versus sorafenib
AXIS (Rini), 2011 NCT00678392	axitinib versus	second-line therapy in patients with metastatic renal cell cancer
Qin, 2012	versus
bevacizumab versus placebo
Yang, 2003	bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks versus placebo	patients with metastatic renal-cell carcinoma
bevacizumab plus interferon alfa versus interferon alpha
CALGB 90206, 2010	bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN- (9 million units subcutaneously three times weekly) versus same dose and schedule of IFN- monotherapy	Patients with previously untreated, metastatic clear cell RCC
AVOREN, 2007	bevacizumab (10 mg/kg every 2 weeks) plus IFN (9 MIU subcutaneously three times a week) versus IFN plus placebo	patients with previously untreated mRCC
BNC105P + everolimus versus everolimus
Disruptor-1,	versus
cabozantinib versus everolimus
METEOR, 2015 NCT01865747	cabozantinib at a dose of 60 mg daily versus everolimus at a dose of 10 mg daily	patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy	open-label
cabozantinib versus sunitinib
CABOSUN, 2017 NCT01835158	cabozantinib (60 mg once per day) versus sunitinib (50 mg once per day; 4 weeks on, 2 weeks off).	untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria	open-label
dovitinib versus sorafenib
GOLD, NCT01223027	dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) versus sorafenib (400 mg orally twice daily)	patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor	open-label
everolimus versus placebo
RECORD-1, 2008 NCT00410124	everolimus 10 mg once daily versus placebo	Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both
everolimus versus sunitinib
RECORD 3, 2014 NCT00903175	everolimus versus sunitinib	patients with metastatic renal cell carcinoma
nivolumab versus everolimus
Chekmate 025 (Motzer), 2015 NCT01668784	3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks versus 10-mg everolimus tablet orally once daily	patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy	open-label
nivolumab + ipilimumab versus sunitinib
CheckMate-214, 2017 NCT02231749	nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks versus sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment	intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma	open-label
pazopanib versus placebo
Sternberg, 2010	pazopanib versus placebo	treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma	double-blind
VEG105192, 2010 NCT00334282	versus	treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma
pazopanib versus sunitinib
COMPARZ, 2013 NCT00720941	continuous dose of pazopanib (800 mg once daily) versus sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment)	patients with clear-cell, metastatic renal-cell carcinoma, first line
sorafenib versus interferon alpha
Escudier, 2009	oral sorafenib 400 mg twice daily versus subcutaneous IFN--2a 9 million U three times weekly	patients with untreated, advanced renal cancer.
sorafenib versus placebo
TARGET, 2007 NCT00073307	continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) versus placebo	patients with renal-cell carcinoma that was resistant to standard therapy
Ratain, 2006	versus	patients with metastatic renal cell carcinoma
sunitinib versus interferon alpha
Motzer, 2007 NCT00083889	repeated 6-week cycles of sunitinib (at a dose of 50 mg given orally once daily for 4 weeks, followed by 2 weeks without treatment) versus interferon alfa (at a dose of 9 MU given subcutaneously three times weekly).	patients with previously untreated, metastatic renal-cell carcinoma
sunitinib versus sorafenib
SWITCH, NCT00732914	versus
temsirolimus versus interferon alpha
ARCC (Hudes) temsirolimus alone, 2007 NCT00065468	25 mg of intravenoustemsirolimus weekly versus 3 million U of interferon alfa (with an increase to 18 millionU) subcutaneously three times weekly	patients with previously untreated, poor-prognosis metastatic renal-cell carcinoma
temsirolimus versus sorafenib
INTORSECT, 2014 NCT00474786	temsirolimus 25 mg once weekly by intravenous (IV) infusion versus sorafenib 400 mg PO twice daily	Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
tivozanib versus sorafenib
TIVO-1, 2013 NCT01030783	tivozanib versus sorafenib	initial targeted therapy in patients with metastatic renal cell carcinoma